MX2021000331A - Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). - Google Patents
Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada).Info
- Publication number
- MX2021000331A MX2021000331A MX2021000331A MX2021000331A MX2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A MX 2021000331 A MX2021000331 A MX 2021000331A
- Authority
- MX
- Mexico
- Prior art keywords
- ada
- immunoassay
- interference
- mitigate
- methods
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862696016P | 2018-07-10 | 2018-07-10 | |
| PCT/US2019/040950 WO2020014194A1 (en) | 2018-07-10 | 2019-07-09 | Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000331A true MX2021000331A (es) | 2021-03-25 |
Family
ID=67544324
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000331A MX2021000331A (es) | 2018-07-10 | 2019-07-09 | Metodos para mitigar la interferencia de la diana farmacologica en un inmunoensayo de anticuerpos antifarmaco (ada). |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12055551B2 (enExample) |
| EP (1) | EP3821255B1 (enExample) |
| JP (3) | JP7493459B2 (enExample) |
| KR (1) | KR102754704B1 (enExample) |
| CN (1) | CN112384808B (enExample) |
| AU (1) | AU2019301614B2 (enExample) |
| BR (1) | BR112020022912A2 (enExample) |
| EA (1) | EA202190237A1 (enExample) |
| ES (1) | ES2993989T3 (enExample) |
| IL (1) | IL277888B2 (enExample) |
| MA (1) | MA53130A (enExample) |
| MX (1) | MX2021000331A (enExample) |
| MY (1) | MY207418A (enExample) |
| SG (1) | SG11202011283TA (enExample) |
| WO (1) | WO2020014194A1 (enExample) |
| ZA (1) | ZA202006409B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
| CN114264814B (zh) * | 2021-12-30 | 2025-03-14 | 苏州和锐生物科技有限公司 | 一种pd-1生物制剂的抗体检测试剂盒及制备方法 |
| CN114324894A (zh) * | 2021-12-31 | 2022-04-12 | 军科正源（北京）药物研究有限责任公司 | 一种检测贝伐珠单抗抗药性抗体的新型分析方法 |
| CN114047343B (zh) * | 2022-01-13 | 2022-05-31 | 美迪西普亚医药科技(上海)有限公司 | 双耐受型抗IgE单抗药物的免疫原性分析试剂盒及其使用方法和应用 |
| WO2023204378A1 (ko) * | 2022-04-19 | 2023-10-26 | 의료법인 성광의료재단 | 혈액 내 항-약물항체 농도 측정을 통한 생물학적 약물에 대한 치료 반응성 예측 방법 |
| CN119790065A (zh) * | 2022-08-24 | 2025-04-08 | 美国安进公司 | 抗药物抗体测定 |
| CN115586337A (zh) * | 2022-09-14 | 2023-01-10 | 杭州赛基生物科技有限公司 | 检测肿瘤伴随诊断相关因子的试剂盒及其制备方法 |
| CN120239821A (zh) * | 2022-09-23 | 2025-07-01 | 默沙东有限责任公司 | 中和抗体测定方法 |
| CN115575468B (zh) * | 2022-09-30 | 2025-08-26 | 华润生物医药有限公司 | 一种检测抗重组人GLP-1-Fc融合蛋白抗体的方法 |
| CN115856322A (zh) * | 2022-12-23 | 2023-03-28 | 同昕生物技术（北京）有限公司 | 用于抗奥马株单抗药物抗体检测的试剂及其应用 |
| CN117805382B (zh) * | 2024-02-28 | 2024-05-03 | 军科正源（北京）药物研究有限责任公司 | 检测抗利妥昔单抗中和抗体的方法 |
| WO2025224166A1 (en) * | 2024-04-23 | 2025-10-30 | F. Hoffmann-La Roche Ag | Anti-drug antibody assays |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856469A (en) * | 1973-01-02 | 1974-12-24 | Syva Corp | Interferant removal from amphetamine immunoassay |
| JPS55145690A (en) | 1979-05-04 | 1980-11-13 | Toyama Chem Co Ltd | Novel penicillin and cephalosporin, and its salt |
| JPS6454356A (en) * | 1987-08-26 | 1989-03-01 | Meidensha Electric Mfg Co Ltd | Method for suppressing non-specific adsorption of antibody to solid phase antigen |
| JPH02138872A (ja) | 1988-11-18 | 1990-05-28 | Asahi Chem Ind Co Ltd | 癌関連物質のための免疫測定方法 |
| WO2005031353A1 (ja) | 2003-09-26 | 2005-04-07 | Matsushita Electric Industrial Co., Ltd. | 免疫反応測定方法、ならびにそれに用いる試薬、キット、及び光学セル |
| EP2142925A1 (en) | 2007-05-07 | 2010-01-13 | Wyeth a Corporation of the State of Delaware | Elimination of interference in immunoassays caused by anti-carbohydrate antibodies |
| WO2009022001A1 (en) * | 2007-08-16 | 2009-02-19 | Novartis Ag | Improvement of drug tolerance in immunogenicity testing |
| CA3141978A1 (en) * | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| JP6563910B2 (ja) | 2013-07-04 | 2019-08-21 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 血清サンプル中の抗薬物抗体を検出するための干渉抑制イムノアッセイ |
| EP4137816B1 (en) | 2014-02-11 | 2025-03-19 | Genzyme Corporation | Assays for detecting the presence or amount of an anti-drug antibody |
| WO2017096262A1 (en) * | 2015-12-04 | 2017-06-08 | Jomoco, Corp. | Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates |
| US20190145985A1 (en) | 2017-11-10 | 2019-05-16 | BioAgilytix Labs, LLC | Method for eliminating target interference |
| JP7161534B2 (ja) | 2017-11-29 | 2022-10-26 | エフ．ホフマン－ラ ロシュ アーゲー | 標的による干渉が抑制された抗薬物抗体アッセイ |
| MX2022011336A (es) * | 2020-03-17 | 2022-10-07 | Regeneron Pharma | Atenuacion de la interferencia de dianas en ensayo de anticuerpos antifarmacos. |
-
2019
- 2019-07-09 BR BR112020022912-1A patent/BR112020022912A2/pt unknown
- 2019-07-09 JP JP2020564556A patent/JP7493459B2/ja active Active
- 2019-07-09 US US16/506,379 patent/US12055551B2/en active Active
- 2019-07-09 WO PCT/US2019/040950 patent/WO2020014194A1/en not_active Ceased
- 2019-07-09 AU AU2019301614A patent/AU2019301614B2/en active Active
- 2019-07-09 KR KR1020207033049A patent/KR102754704B1/ko active Active
- 2019-07-09 EP EP19749872.8A patent/EP3821255B1/en active Active
- 2019-07-09 MX MX2021000331A patent/MX2021000331A/es unknown
- 2019-07-09 MA MA053130A patent/MA53130A/fr unknown
- 2019-07-09 MY MYPI2020005155A patent/MY207418A/en unknown
- 2019-07-09 CN CN201980046236.XA patent/CN112384808B/zh active Active
- 2019-07-09 IL IL277888A patent/IL277888B2/en unknown
- 2019-07-09 EA EA202190237A patent/EA202190237A1/ru unknown
- 2019-07-09 SG SG11202011283TA patent/SG11202011283TA/en unknown
- 2019-07-09 ES ES19749872T patent/ES2993989T3/es active Active
-
2020
- 2020-10-15 ZA ZA2020/06409A patent/ZA202006409B/en unknown
-
2024
- 2024-02-20 JP JP2024023599A patent/JP2024045646A/ja active Pending
- 2024-07-03 US US18/763,265 patent/US20240353423A1/en active Pending
-
2025
- 2025-10-23 JP JP2025179025A patent/JP2026012856A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7493459B2 (ja) | 2024-05-31 |
| US12055551B2 (en) | 2024-08-06 |
| IL277888A (en) | 2020-11-30 |
| JP2021531448A (ja) | 2021-11-18 |
| KR102754704B1 (ko) | 2025-01-20 |
| AU2019301614A1 (en) | 2020-10-22 |
| ES2993989T3 (en) | 2025-01-15 |
| ZA202006409B (en) | 2025-07-30 |
| KR20210031854A (ko) | 2021-03-23 |
| EP3821255A1 (en) | 2021-05-19 |
| CA3098206A1 (en) | 2020-01-16 |
| MA53130A (fr) | 2021-05-19 |
| EA202190237A1 (ru) | 2021-04-15 |
| JP2026012856A (ja) | 2026-01-27 |
| IL277888B2 (en) | 2025-04-01 |
| CN112384808B (zh) | 2024-10-11 |
| US20240353423A1 (en) | 2024-10-24 |
| WO2020014194A1 (en) | 2020-01-16 |
| BR112020022912A2 (pt) | 2021-02-23 |
| CN112384808A (zh) | 2021-02-19 |
| JP2024045646A (ja) | 2024-04-02 |
| MY207418A (en) | 2025-02-26 |
| SG11202011283TA (en) | 2020-12-30 |
| EP3821255B1 (en) | 2024-08-28 |
| IL277888B1 (en) | 2024-12-01 |
| AU2019301614B2 (en) | 2025-11-20 |
| US20200018770A1 (en) | 2020-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006409B (en) | Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay | |
| MX2024013186A (es) | Ensayo de anticuerpo antifarmaco con supresion de interferencia del objetivo | |
| SA519402365B1 (ar) | تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية التائية | |
| MX2019010282A (es) | Formulacion de anticuerpos monoclonales. | |
| BR112015022260A2 (pt) | anticorpo monoclonal, polinucleotídeo, composição farmacêutica, fragmento isolado de tau, uso de um anticorpo, método de triagem de um agente e ácido nucleico | |
| PE20191708A1 (es) | ANTICUERPOS DE UNION A VISTA A pH ACIDO | |
| PE20221282A1 (es) | Anticuerpos que se unen a hla-a2/mage-a4 | |
| AR119997A1 (es) | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso | |
| AR101846A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| BR112013021350A2 (pt) | anticorpo e antígeno reconhecido de células iniciadoras de tumor e o uso destes | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| BRPI0919853B8 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente ao receptor de interleucina-4 humano (hil-4r) e seus usos | |
| EA202091810A1 (ru) | Антитела к b7-h4 и способы их применения | |
| BR112022009602A2 (pt) | Anticorpos anti-cd79 ch38c-cd79 chctric, células car-t, e usos dos mesmos | |
| BR112022024262A2 (pt) | Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april | |
| BR112022005404A2 (pt) | Anticorpo monoclonal contra a proteína de ativação de fibroblastos canina que reage de forma cruzada com a proteína de ativação de fibroblastos de camundongo e humana (fap) | |
| BR112018007842A2 (pt) | imunoensaio para a detecção de cininogênio clivado de alto peso molecular, método, anticorpo isolado, kit para detectar um cininogênio de alto peso molecular clivado (hmwk) | |
| PE20220004A1 (es) | Anticuerpos monoclonales especificos para el antigeno p del virus respiratorio sincicial humano (vrsh), producidos y secretados por hibridomas celulares, utiles para la deteccion y el diagnostico de la infeccion causada por vrsh | |
| BR112021011351A2 (pt) | Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica | |
| BR112022000481A2 (pt) | Conjuntos de anticorpos e de ácidos nucleicos, vetor de expressão, célula hospedeira e métodos de pré-direcionamento de radioimunoterapia e de direcionamento de um radioisótopo | |
| EA201990253A1 (ru) | Гуманизированные антитела против s100a9 и их применение | |
| ECSP22056627A (es) | Anticuerpos contra la integrina alfa 11 beta 1 | |
| TW200740842A (en) | Monoclonal antibodies, hybridoma cell lines, methods and kits for detecting phytase | |
| MX2017005156A (es) | Metodo para determinacion de anticuerpos de anti-farmaco contra anticuerpo de farmaco humano o humanizado de funcion efectora suprimida. | |
| BR112022003471A2 (pt) | Sistema receptor de antígeno quimérico e usos do mesmo |